52.89

0.15% -0.08

Alkermes Plc (ALKS)

Overview News Price History Option Chain Financials Why ALKS Down? Discussions Forecast Stock Split

Alkermes Plc stock is traded at $52.89, with a volume of 1.29M. It is down -0.15% in the last 24 hours and up +4.84% over the past month. Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Previous Close:

$52.97

Open:

$53.38

24h Volume:

1.29M

Relative Volume:

0.60

Market Cap:

$8.82B

Revenue:

$1.56B

Net Income/Loss:

$152.72M

P/E Ratio:

58.81

EPS:

0.8994

Net Cash Flow:

$221.80M

1W Performance:

+0.32%

1M Performance:

+4.84%

6M Performance:

+57.36%

1Y Performance:

+99.36%

1-Day Range:

$52.48

$53.88

1-Week Range:

$51.25

$53.88

52-Week Range:

$25.16

$55.67

Alkermes Plc Stock (ALKS) Company Profile

Name

Alkermes Plc

Sector

Healthcare (1071)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

00-353-1-772-8000

Address

CONNAUGHT HOUSE, DUBLIN 4

Employee

2,050

Twitter

@alkermes

Next Earnings Date

2026-07-28

Latest SEC Filings

ALKS's Discussions on Twitter

Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALKS Alkermes Plc	52.89	8.82B	1.56B	152.72M	221.80M	0.8994
TAK Takeda Pharmaceutical Co Adr	17.24	55.06B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.78	43.07B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	30.81	35.88B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.35	31.59B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	528.47	26.32B	3.17B	1.29B	1.01B	27.09

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-29-26	Downgrade	BofA Securities	Neutral → Underperform
Feb-24-26	Initiated	Wolfe Research	Outperform
Nov-11-25	Initiated	Truist	Buy
Sep-26-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Sep-03-25	Initiated	Wells Fargo	Overweight
Jul-15-25	Initiated	Goldman	Buy
Jun-17-25	Upgrade	UBS	Neutral → Buy
May-28-25	Initiated	Needham	Buy
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform
Mar-04-25	Upgrade	UBS	Sell → Neutral
Feb-11-25	Initiated	Deutsche Bank	Buy
Nov-05-24	Upgrade	Stifel	Hold → Buy
Jun-17-24	Initiated	TD Cowen	Buy
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-20-24	Downgrade	UBS	Neutral → Sell
Nov-20-23	Resumed	JP Morgan	Neutral
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-16-22	Initiated	Piper Sandler	Neutral
Apr-22-22	Resumed	Goldman	Buy
Apr-20-22	Initiated	Goldman	Buy
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight
Dec-01-21	Initiated	Citigroup	Neutral
Oct-07-21	Upgrade	Jefferies	Hold → Buy
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform
Oct-15-20	Upgrade	Mizuho	Neutral → Buy
Jul-30-20	Downgrade	Goldman	Neutral → Sell
Feb-14-20	Downgrade	BofA/Merrill	Buy → Neutral
Feb-14-20	Reiterated	H.C. Wainwright	Neutral
Feb-14-20	Downgrade	JP Morgan	Overweight → Neutral
Feb-06-20	Initiated	Mizuho	Neutral
Jan-31-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Sep-05-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jul-15-19	Upgrade	Goldman	Sell → Neutral
May-31-19	Initiated	H.C. Wainwright	Neutral
May-01-19	Downgrade	Citigroup	Buy → Neutral
Dec-19-18	Downgrade	Goldman	Neutral → Sell
Dec-14-18	Initiated	Wolfe Research	Underperform
Dec-13-18	Downgrade	Credit Suisse	Outperform → Underperform
Nov-05-18	Initiated	Piper Jaffray	Neutral
Aug-07-18	Initiated	Stifel	Hold
Jun-21-18	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jun-06-18	Initiated	B. Riley FBR, Inc.	Buy
May-16-18	Upgrade	Citigroup	Neutral → Buy
May-11-18	Initiated	BofA/Merrill	Buy

View All

Alkermes Plc Stock (ALKS) Latest News

Jul 24, 2026

Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Jul 21, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 21, 2026

Jul 20, 2026

Stifel raises Alkermes stock price target on orexin program outlook By Investing.com - Investing.com South Africa

Jul 20, 2026

Stifel raises Alkermes stock price target on orexin program outlook - Investing.com

Jul 20, 2026

ALKS Upgraded by Stifel -- Price Target Raised to $63 - GuruFocus

Jul 20, 2026

Jul 16, 2026

(ALKS) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jul 16, 2026

Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS) - simplywall.st

Jul 16, 2026

Jul 15, 2026

Alkermes to Report Second Quarter Financial Results on July 28, 2026 - Moomoo

Jul 15, 2026

Jul 14, 2026

Press Release: Alkermes to Report Second Quarter Financial Results on July 28, 2026 - Moomoo

Jul 14, 2026

Narcolepsy Treatments Are Advancing. Can Access? - Sleep Review

Alkermes Plc (ALKS)

Alkermes Plc Stock (ALKS) Company Profile

Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Alkermes Plc Stock (ALKS) Latest News